CIP2A is required for malignant cellular growth and tumor formation and is overexpressed in several human cancers: head and neck squamous cell carcimona, colon cancer, gastric cancer, breast cancer, prostate cancer, and lung caner.
| Inventor | Institute |
|---|---|
| Edward Chan | University of Florida Research Foundation |
| Cat. #: | 158414 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Cell signaling and signal transduction |
| Application: | WB ; IP |
| Target: | Cancerous Inhibitor of Protein Phosphatase 2A |
| Reactivity: | Human ; Rat ; Mouse |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | CIP2A |
|---|---|
| Product description: | CIP2A is an oncoprotein that inhibits PP2A tumor suppressor activity in human malignancies by preventing degredation of c-Myc and regulates the phosphorylation of many oncoproteins. CIP2A is required for malignant cellular growth and tumor formation and is overexpressed in several human cancers: head and neck squamous cell carcimona, colon cancer, gastric cancer, breast cancer, prostate cancer, and lung caner. |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 kappa |
| Immunogen: | MAb were generated using the C-terminal third of the recombinant human protein as antigen |
| Target background: | CIP2A is an oncoprotein that inhibits PP2A tumor suppressor activity in human malignancies by preventing degredation of c-Myc and regulates the phosphorylation of many oncoproteins. CIP2A is required for malignant cellular growth and tumor formation and is overexpressed in several human cancers: head and neck squamous cell carcimona, colon cancer, gastric cancer, breast cancer, prostate cancer, and lung caner. |
|---|
| Format: | Liquid |
|---|---|
| Shipping conditions: | Dry ice |
| References: |
Wei et al. 2019. Oncol Lett. 17(3):3211-3218. PMID: 30867751. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151023 | Anti-IL12 [1-1D5] |
Key Info
Anti-IL12 [1-1D5]
|
View Tool | |||||||||||||||||||
| 151031 | Anti-RuvA [RuvA 12C6] |
Key Info
Anti-RuvA [RuvA 12C6]
|
View Tool | |||||||||||||||||||
| 151033 | Anti-HSVUL42 [13C9] |
Key Info
Anti-HSVUL42 [13C9]
|
View Tool | |||||||||||||||||||
| 151018 | Anti-Mos [R38.1] |
Key Info
Anti-Mos [R38.1]
|
View Tool | |||||||||||||||||||
| 151020 | Anti-CyclinB1 [V143.1] |
Key Info
Anti-CyclinB1 [V143.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.